+5.6%
CDE vs MRNA
+945.0%
-939.4%
-51.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +8.7% | +13.1% | -4.4% | +7.3% |
| 7D | +1.1% | +20.6% | -19.5% | -0.9% |
| 30D | -14.5% | +27.1% | -41.6% | -16.8% |
| 3M | -10.1% | +353.4% | -363.4% | -30.9% |
| 6M | -16.9% | +446.3% | -463.1% | -40.6% |
| YTD | -18.1% | +776.2% | -794.3% | -47.7% |
| 1Y | +5.6% | +987.9% | -982.3% | -38.6% |
| All | +5.6% | +945.0% | -939.4% | -38.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling